by Lyla El-Fayomi | Mar 12, 2026
Somehow we are already into March, and spring – at least in some places – feels close by. To catch you up, I’ve put together a recap of some of the research that scientists were buzzing about in the field of regenerative medicine from 2025; I cover the good, the bad,...
by Laya Kiani | Feb 12, 2026
In 2025, cell and gene therapy (CGT) showed growing clinical familiarity even as access and reimbursement challenges persisted. Providers and payers increasingly trusted and valued CGTs, supporting the continued expansion of late-stage programs. However, startup...
by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Krystal Jacques | Jan 19, 2026
Hunter syndrome is one of the mucopolysaccharidoses, a group of lysosomal storage disorders caused by specific genetic mutations and missing enzymes. In Hunter syndrome, mutations in the X-linked iduronate-2-sulfatase (IDS) lead to deficiencies in the IDS enzyme,...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Cal Strode | Dec 1, 2025
To mark World AIDS Day, I revisited the rapidly shifting HIV cure research landscape, checking in on International AIDS Society (IAS) 2025 to see how things have evolved since 2021, when I last covered progress for Signals. Curative approaches are starting to move on...
Comments